SEC Tracker
Get the app

Ginkgo Bioworks Holdings DNA

Ginkgo Bioworks reported a $40.98 million net loss for Q3 2026.

Ginkgo Bioworks Holdings (DNA) filed a 10-Q with the SEC on Nov 9, 2026, 4:52 pm ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Revenue of $27.71 million for the three months ended Sep 30, 2026.
  2. Net loss of $40.98 million for the three months ended Sep 30, 2026.
  3. Cash and equivalents of $84.5 million as of Sep 30, 2026.

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Ginkgo Bioworks Holdings files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

No new risk factors or legal mentions.

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Revenue$27.71M$20.16M+38%
Operating income and margin−$43.63M · -157.5%−$58.55M · -290.5%+26%, margin +133 pts
Net income−$40.98M−$46.71M+12%
Operating cash flow−$28.35M−$44.27M+36%
Cash$84.5M$84.54M0%
Backlog (remaining performance obligations)$125.6M$113M+11%

Data on this page was fetched . The filing on SEC.gov is the record.